miRNA signature for diagnosis and indication of responsiveness to therapy
|
Categories |
Oncology, Pediatrics, Diagnostics |
|
Development Stage |
Diagnostic- Clinical POC; Therapeutic-pre-clinical |
|
Patent Status |
Provisional patent application filed |
|
Market |
GlobalData estimated the global osteosarcoma therapeutics market to be worth $67 million in 2010, forecast to grow at a compound annual growth rate (CAGR) of 6.1% to reach $102 million in 2017. |
Highlights
-
Pediatric Osteosarcoma is an orphan disease
-
Treatment paradigms and survival rates have not improved in two decades.
-
A delay in diagnosis for childhood osteosarcoma is not uncommon because the symptoms, such as pain and swelling, can be easily mistaken for normal teenager activity
-
A signature of microRNA expression associated with the pathogenesis and progression of osteosarcoma has been identified.
-
Research was conducted on clinical samples.
Our Innovation
Unique signatures of microRNA expression in osteosarcoma associated with the disease’s character and pathogenesis that indicate clinical metastasis and response to chemotherapy.
Key Features
-
High expression of miR-181a, miR-181b, and miR-181c together with reduced expression of miR-16, miR-29b and miR-142.5p serve as a signature reflecting the pathogenesis of osteosarcoma.
-
Higher expression of miR-27a and miR-181c* in pre-treatment biopsy samples characterizes a likelihood of the development of clinical metastatic disease.
-
Higher expression of miR-451 and miR-15b in pre-treatment samples correlates to a subsequent positive response to chemotherapy.
Development Milestones
Pre-clinical package
The Opportunity
Seeking to license out the technology or to collaborate with a strategic partner.
1586128900.png)